Alba celiac compound meets in Phase IIb trial

Alba Therapeutics Corp. (Baltimore, Md.) said thrice-daily oral larazotide ( AT-1001) met the primary endpoint in the Phase IIb CLIN1001-012 trial to treat celiac disease. Larazotide improved the celiac disease domains of the gastrointestinal symptoms rating scale from baseline to week 12 vs. placebo. The double-blind, North American trial enrolled 342 celiac disease patients with persistent symptoms despite being on a gluten-free diet. Alba said it has started planning Phase III trials, but declined to disclose details. Larazotide is a tight junction regulator. ...